Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

By HospiMedica International staff writers
Posted on 21 Oct 2025

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions. More...

Surgeons often operate without real-time molecular data, making it difficult to identify tumor boundaries or tailor the extent of removal. Now, a new genetic testing system enables the detection of key brain tumor mutations in as little as 25 minutes, allowing immediate guidance during surgery.

Developed by researchers at Nagoya University (Nagoya, Japan), the system uses the GeneSoC high-speed real-time PCR device, which incorporates advanced microfluidic technology. The team designed an original protocol enabling high-quality DNA extraction using only heat incubation, eliminating lengthy preparation steps. This combination allows for ultra-fast, on-site genetic testing directly from tumor samples collected during surgery.

The system was tested on 120 cases of brain tumors to detect mutations in isocitrate dehydrogenase (IDH1) and telomerase reverse transcriptase (TERT) promoters—key diagnostic markers for diffuse glioma. Results showed remarkable accuracy, with 98.5% sensitivity and 98.2% specificity for IDH1, and 100% for TERT mutation detection. The average testing time per sample was just 22−25 minutes, as reported in Neuro-Oncology.

By identifying genetic mutations intraoperatively, surgeons can more precisely define tumor margins and distinguish cancerous tissue from normal brain cells. This approach could improve surgical outcomes by maximizing tumor removal while minimizing damage to healthy tissue. The researchers also confirmed that the system accurately defines tumor boundaries, a critical step for surgical decision-making.

“We demonstrated that our genetic analysis system enables molecular diagnosis during surgery. This system identifies tumor boundaries, helping surgeons define resection margins. This marks a significant clinical achievement,” said researcher Sachi Maeda. “Notably, our system's ability to intraoperatively identify TERT promoter mutations—which cannot be detected through immunostaining—represents a groundbreaking advancement globally. We believe this technology will significantly enhance the precision of glioma surgery in the near future.”

Related Links:
Nagoya University


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.